华润双鹤：关于全资子公司部分药品获得药品注册证书的公告

Core Viewpoint - China Resources Double Crane announced the receipt of drug registration certificates for three products from the National Medical Products Administration, indicating a significant step in expanding its pharmaceutical portfolio [1] Group 1: Company Developments - The wholly-owned subsidiaries of China Resources Double Crane, including Beijing Wanhui Double Crane Pharmaceutical Co., Ltd., China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd., and Double Crane Pharmaceutical (Hainan) Co., Ltd., received registration certificates for Amlodipine Benazepril Capsules, Tocilizumab Sustained-Release Tablets, and Vornorex Fumarate Tablets [1]